Vivoryon Therapeutics AG stock analysis
Vivoryon Therapeutics AG (0R3M) Share Price & Analysis
0R3M Stock Chart & Stats
- Day’s Range
- EUR 0.72 - EUR 0.74
- 52-Week Range
- EUR 0.55 - EUR 1.65
- Previous Close
- EUR 0.74
- Volume
- N/A
- Average Volume (3M)
- 1,125
- Market Cap
- EUR 21.62M
- Enterprise Value
- EUR 29.61M
- Total Cash (Recent Filing)
- EUR 2.45M
- Total Debt (Recent Filing)
- EUR 76.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.57
- Next Earnings
- Apr 29, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage limits fixed financial obligations and reduces the balance-sheet burden from debt. This provides more flexibility than a highly indebted structure, although the benefit is tempered by the company’s declining equity base and continuing cash needs.
Improved Loss And Cash Burn
The substantial reduction in reported net loss and operating cash burn during 2025 indicates some improvement in financial performance. If maintained, this could extend the company’s operating runway, though cash generation remains negative and the business is not yet self-funding.
Platform-Based Drug Discovery
A defined enzyme-targeting platform and neuroscience pipeline give Vivoryon a focused basis for developing multiple small-molecule medicines. Concentration on diseases with high unmet need may support long-term opportunity if the platform produces clinically viable candidates.
Bears Say
No Recent Revenue And Persistent Losses
The absence of reported revenue in 2024–2025, together with negative gross profit and continuing operating losses, shows that the business has not yet established commercial earnings power. This leaves future financial sustainability dependent on successful development and eventual monetization.
Negative Cash Generation
Persistent negative operating and free cash flow means current activities do not fund the company’s operations. Continued cash consumption can require external financing or further balance-sheet contraction, creating an ongoing constraint on development spending and strategic flexibility.
Shrinking Equity And Asset Base
The sharp contraction in equity and total assets indicates that prior cash consumption has materially reduced financial resources. A smaller asset base provides less protection against further losses and leaves less flexibility to sustain development or absorb operating setbacks.
Vivoryon Therapeutics AG News
0R3M FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
What is Vivoryon Therapeutics AG’s market cap?
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
How were Vivoryon Therapeutics AG’s earnings last quarter?
Is Vivoryon Therapeutics AG overvalued?
Does Vivoryon Therapeutics AG pay dividends?
What is Vivoryon Therapeutics AG’s EPS estimate?
How many shares outstanding does Vivoryon Therapeutics AG have?
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Frank T. Weber
- Employees
- 13
- Website
- www.vivoryon.com
- Address
- Weinbergweg 22, Halle, SA, 06120, DE
Vivoryon Therapeutics AG (0R3M) Earnings & Revenues
0R3M Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted significant clinical and financial progress, particularly in reducing expenses and advancing the varoglutamstat program, while also addressing challenges such as a reduced cash position and the need for additional financing for future studies.
View all GB:0R3M earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 6 | 11 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 4 | 0 | 8 |










